nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—CYP2D6—Gefitinib—lung cancer	0.035	0.125	CbGbCtD
Pergolide—CYP2D6—Vinorelbine—lung cancer	0.027	0.096	CbGbCtD
Pergolide—CYP3A4—Topotecan—lung cancer	0.0243	0.0867	CbGbCtD
Pergolide—CYP3A4—Gefitinib—lung cancer	0.0223	0.0793	CbGbCtD
Pergolide—CYP3A4—Teniposide—lung cancer	0.0216	0.0769	CbGbCtD
Pergolide—CYP2D6—Erlotinib—lung cancer	0.0207	0.0737	CbGbCtD
Pergolide—CYP3A4—Vinorelbine—lung cancer	0.0171	0.0611	CbGbCtD
Pergolide—CYP2D6—Vinblastine—lung cancer	0.0166	0.0592	CbGbCtD
Pergolide—CYP3A4—Crizotinib—lung cancer	0.0136	0.0486	CbGbCtD
Pergolide—CYP3A4—Erlotinib—lung cancer	0.0132	0.0469	CbGbCtD
Pergolide—CYP3A4—Paclitaxel—lung cancer	0.012	0.0429	CbGbCtD
Pergolide—CYP3A4—Irinotecan—lung cancer	0.0119	0.0423	CbGbCtD
Pergolide—CYP3A4—Vinblastine—lung cancer	0.0106	0.0376	CbGbCtD
Pergolide—CYP2D6—Doxorubicin—lung cancer	0.0102	0.0364	CbGbCtD
Pergolide—CYP3A4—Etoposide—lung cancer	0.00952	0.0339	CbGbCtD
Pergolide—CYP3A4—Docetaxel—lung cancer	0.00871	0.031	CbGbCtD
Pergolide—CYP3A4—Doxorubicin—lung cancer	0.00649	0.0231	CbGbCtD
Pergolide—HTR2A—phrenic nerve—lung cancer	0.00535	0.374	CbGeAlD
Pergolide—HTR2A—pulmonary artery—lung cancer	0.00194	0.136	CbGeAlD
Pergolide—ADRA1D—epithelium—lung cancer	0.000735	0.0514	CbGeAlD
Pergolide—DRD2—respiratory system—lung cancer	0.000495	0.0346	CbGeAlD
Pergolide—ADRA1A—epithelium—lung cancer	0.000422	0.0295	CbGeAlD
Pergolide—ADRA2C—bronchus—lung cancer	0.000396	0.0277	CbGeAlD
Pergolide—ADRA2C—trachea—lung cancer	0.000356	0.0249	CbGeAlD
Pergolide—KCNH2—cardiac atrium—lung cancer	0.000339	0.0237	CbGeAlD
Pergolide—ADRA2C—cardiac atrium—lung cancer	0.000334	0.0234	CbGeAlD
Pergolide—HTR2A—respiratory system—lung cancer	0.000326	0.0228	CbGeAlD
Pergolide—HTR2B—lung—lung cancer	0.000325	0.0227	CbGeAlD
Pergolide—ADRA2A—bronchus—lung cancer	0.000316	0.0221	CbGeAlD
Pergolide—KCNH2—bone marrow—lung cancer	0.000286	0.02	CbGeAlD
Pergolide—ADRA2A—trachea—lung cancer	0.000284	0.0199	CbGeAlD
Pergolide—HTR2A—epithelium—lung cancer	0.000273	0.0191	CbGeAlD
Pergolide—ADRA2A—cardiac atrium—lung cancer	0.000267	0.0187	CbGeAlD
Pergolide—DRD2—lung—lung cancer	0.000263	0.0184	CbGeAlD
Pergolide—ADRA2C—lung—lung cancer	0.000255	0.0179	CbGeAlD
Pergolide—HTR2A—trachea—lung cancer	0.000241	0.0169	CbGeAlD
Pergolide—HTR2B—lymph node—lung cancer	0.000222	0.0155	CbGeAlD
Pergolide—ADRA2A—lung—lung cancer	0.000204	0.0143	CbGeAlD
Pergolide—KCNH2—lymph node—lung cancer	0.000177	0.0124	CbGeAlD
Pergolide—ADRA2C—lymph node—lung cancer	0.000175	0.0122	CbGeAlD
Pergolide—HTR2A—lung—lung cancer	0.000173	0.0121	CbGeAlD
Pergolide—Rash—Vinorelbine—lung cancer	0.000163	0.000329	CcSEcCtD
Pergolide—Dermatitis—Vinorelbine—lung cancer	0.000163	0.000329	CcSEcCtD
Pergolide—Abdominal distension—Doxorubicin—lung cancer	0.000163	0.000329	CcSEcCtD
Pergolide—Hypotension—Paclitaxel—lung cancer	0.000162	0.000328	CcSEcCtD
Pergolide—Headache—Vinorelbine—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Syncope—Docetaxel—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Conjunctivitis—Methotrexate—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Influenza—Doxorubicin—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Asthma—Doxorubicin—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Dysphagia—Doxorubicin—lung cancer	0.000162	0.000327	CcSEcCtD
Pergolide—Leukopenia—Docetaxel—lung cancer	0.000162	0.000326	CcSEcCtD
Pergolide—Eosinophilia—Doxorubicin—lung cancer	0.00016	0.000323	CcSEcCtD
Pergolide—Sweating—Methotrexate—lung cancer	0.00016	0.000322	CcSEcCtD
Pergolide—Palpitations—Docetaxel—lung cancer	0.00016	0.000322	CcSEcCtD
Pergolide—Feeling abnormal—Cisplatin—lung cancer	0.000159	0.000322	CcSEcCtD
Pergolide—Paraesthesia—Etoposide—lung cancer	0.000159	0.000321	CcSEcCtD
Pergolide—Haematuria—Methotrexate—lung cancer	0.000159	0.000321	CcSEcCtD
Pergolide—Loss of consciousness—Docetaxel—lung cancer	0.000159	0.00032	CcSEcCtD
Pergolide—Pancreatitis—Doxorubicin—lung cancer	0.000159	0.00032	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000158	0.00032	CcSEcCtD
Pergolide—Dyspnoea—Etoposide—lung cancer	0.000158	0.000319	CcSEcCtD
Pergolide—Somnolence—Etoposide—lung cancer	0.000158	0.000318	CcSEcCtD
Pergolide—Cough—Docetaxel—lung cancer	0.000158	0.000318	CcSEcCtD
Pergolide—Angina pectoris—Doxorubicin—lung cancer	0.000157	0.000318	CcSEcCtD
Pergolide—Insomnia—Paclitaxel—lung cancer	0.000157	0.000317	CcSEcCtD
Pergolide—Epistaxis—Methotrexate—lung cancer	0.000157	0.000317	CcSEcCtD
Pergolide—Convulsion—Docetaxel—lung cancer	0.000156	0.000316	CcSEcCtD
Pergolide—Paraesthesia—Paclitaxel—lung cancer	0.000156	0.000315	CcSEcCtD
Pergolide—Hypertension—Docetaxel—lung cancer	0.000156	0.000315	CcSEcCtD
Pergolide—Bronchitis—Doxorubicin—lung cancer	0.000155	0.000314	CcSEcCtD
Pergolide—Dyspnoea—Paclitaxel—lung cancer	0.000155	0.000313	CcSEcCtD
Pergolide—Somnolence—Paclitaxel—lung cancer	0.000155	0.000312	CcSEcCtD
Pergolide—Decreased appetite—Etoposide—lung cancer	0.000154	0.000311	CcSEcCtD
Pergolide—Chest pain—Docetaxel—lung cancer	0.000154	0.00031	CcSEcCtD
Pergolide—Myalgia—Docetaxel—lung cancer	0.000154	0.00031	CcSEcCtD
Pergolide—Arthralgia—Docetaxel—lung cancer	0.000154	0.00031	CcSEcCtD
Pergolide—Nausea—Vinorelbine—lung cancer	0.000153	0.00031	CcSEcCtD
Pergolide—Dyspepsia—Paclitaxel—lung cancer	0.000153	0.000309	CcSEcCtD
Pergolide—Body temperature increased—Cisplatin—lung cancer	0.000153	0.000309	CcSEcCtD
Pergolide—Asthenia—Irinotecan—lung cancer	0.000153	0.000309	CcSEcCtD
Pergolide—Constipation—Etoposide—lung cancer	0.000152	0.000306	CcSEcCtD
Pergolide—Pain—Etoposide—lung cancer	0.000152	0.000306	CcSEcCtD
Pergolide—Dysuria—Doxorubicin—lung cancer	0.000151	0.000305	CcSEcCtD
Pergolide—Decreased appetite—Paclitaxel—lung cancer	0.000151	0.000305	CcSEcCtD
Pergolide—Dry mouth—Docetaxel—lung cancer	0.00015	0.000304	CcSEcCtD
Pergolide—Hepatitis—Methotrexate—lung cancer	0.000149	0.000302	CcSEcCtD
Pergolide—Pollakiuria—Doxorubicin—lung cancer	0.000149	0.000302	CcSEcCtD
Pergolide—Asthenia—Gemcitabine—lung cancer	0.000149	0.000301	CcSEcCtD
Pergolide—Constipation—Paclitaxel—lung cancer	0.000149	0.0003	CcSEcCtD
Pergolide—Pain—Paclitaxel—lung cancer	0.000149	0.0003	CcSEcCtD
Pergolide—Confusional state—Docetaxel—lung cancer	0.000149	0.0003	CcSEcCtD
Pergolide—Pharyngitis—Methotrexate—lung cancer	0.000148	0.0003	CcSEcCtD
Pergolide—Oedema—Docetaxel—lung cancer	0.000147	0.000298	CcSEcCtD
Pergolide—Weight increased—Doxorubicin—lung cancer	0.000147	0.000297	CcSEcCtD
Pergolide—Pruritus—Gemcitabine—lung cancer	0.000147	0.000297	CcSEcCtD
Pergolide—Infection—Docetaxel—lung cancer	0.000146	0.000296	CcSEcCtD
Pergolide—Weight decreased—Doxorubicin—lung cancer	0.000146	0.000295	CcSEcCtD
Pergolide—Feeling abnormal—Etoposide—lung cancer	0.000146	0.000295	CcSEcCtD
Pergolide—Hyperglycaemia—Doxorubicin—lung cancer	0.000146	0.000295	CcSEcCtD
Pergolide—Diarrhoea—Irinotecan—lung cancer	0.000146	0.000294	CcSEcCtD
Pergolide—Pneumonia—Doxorubicin—lung cancer	0.000145	0.000293	CcSEcCtD
Pergolide—Gastrointestinal pain—Etoposide—lung cancer	0.000145	0.000293	CcSEcCtD
Pergolide—Shock—Docetaxel—lung cancer	0.000145	0.000293	CcSEcCtD
Pergolide—Thrombocytopenia—Docetaxel—lung cancer	0.000144	0.000291	CcSEcCtD
Pergolide—Visual impairment—Methotrexate—lung cancer	0.000144	0.000291	CcSEcCtD
Pergolide—Tachycardia—Docetaxel—lung cancer	0.000144	0.00029	CcSEcCtD
Pergolide—Feeling abnormal—Paclitaxel—lung cancer	0.000143	0.000289	CcSEcCtD
Pergolide—Gastrointestinal pain—Paclitaxel—lung cancer	0.000142	0.000287	CcSEcCtD
Pergolide—Diarrhoea—Gemcitabine—lung cancer	0.000142	0.000287	CcSEcCtD
Pergolide—Renal failure—Doxorubicin—lung cancer	0.000142	0.000286	CcSEcCtD
Pergolide—Neuropathy peripheral—Doxorubicin—lung cancer	0.000141	0.000285	CcSEcCtD
Pergolide—Dizziness—Irinotecan—lung cancer	0.000141	0.000285	CcSEcCtD
Pergolide—Jaundice—Doxorubicin—lung cancer	0.000141	0.000284	CcSEcCtD
Pergolide—Anorexia—Docetaxel—lung cancer	0.00014	0.000284	CcSEcCtD
Pergolide—Abdominal pain—Etoposide—lung cancer	0.00014	0.000283	CcSEcCtD
Pergolide—Body temperature increased—Etoposide—lung cancer	0.00014	0.000283	CcSEcCtD
Pergolide—Urinary tract infection—Doxorubicin—lung cancer	0.00014	0.000283	CcSEcCtD
Pergolide—Conjunctivitis—Doxorubicin—lung cancer	0.00014	0.000283	CcSEcCtD
Pergolide—Eye disorder—Methotrexate—lung cancer	0.00014	0.000282	CcSEcCtD
Pergolide—ADRA2A—lymph node—lung cancer	0.000139	0.00976	CbGeAlD
Pergolide—Tinnitus—Methotrexate—lung cancer	0.000139	0.000281	CcSEcCtD
Pergolide—Asthenia—Cisplatin—lung cancer	0.000139	0.00028	CcSEcCtD
Pergolide—Sweating—Doxorubicin—lung cancer	0.000138	0.000279	CcSEcCtD
Pergolide—Hypotension—Docetaxel—lung cancer	0.000138	0.000278	CcSEcCtD
Pergolide—Haematuria—Doxorubicin—lung cancer	0.000137	0.000278	CcSEcCtD
Pergolide—Abdominal pain—Paclitaxel—lung cancer	0.000137	0.000277	CcSEcCtD
Pergolide—Body temperature increased—Paclitaxel—lung cancer	0.000137	0.000277	CcSEcCtD
Pergolide—Epistaxis—Doxorubicin—lung cancer	0.000136	0.000275	CcSEcCtD
Pergolide—Vomiting—Irinotecan—lung cancer	0.000136	0.000274	CcSEcCtD
Pergolide—Sinusitis—Doxorubicin—lung cancer	0.000135	0.000273	CcSEcCtD
Pergolide—Rash—Irinotecan—lung cancer	0.000134	0.000271	CcSEcCtD
Pergolide—Dermatitis—Irinotecan—lung cancer	0.000134	0.000271	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000134	0.000271	CcSEcCtD
Pergolide—Chills—Methotrexate—lung cancer	0.000134	0.000271	CcSEcCtD
Pergolide—Headache—Irinotecan—lung cancer	0.000134	0.00027	CcSEcCtD
Pergolide—Insomnia—Docetaxel—lung cancer	0.000133	0.000269	CcSEcCtD
Pergolide—Diarrhoea—Cisplatin—lung cancer	0.000132	0.000267	CcSEcCtD
Pergolide—Paraesthesia—Docetaxel—lung cancer	0.000132	0.000267	CcSEcCtD
Pergolide—Alopecia—Methotrexate—lung cancer	0.000132	0.000267	CcSEcCtD
Pergolide—Vomiting—Gemcitabine—lung cancer	0.000132	0.000267	CcSEcCtD
Pergolide—Bradycardia—Doxorubicin—lung cancer	0.000132	0.000266	CcSEcCtD
Pergolide—Dyspnoea—Docetaxel—lung cancer	0.000131	0.000265	CcSEcCtD
Pergolide—Somnolence—Docetaxel—lung cancer	0.000131	0.000265	CcSEcCtD
Pergolide—Rash—Gemcitabine—lung cancer	0.000131	0.000264	CcSEcCtD
Pergolide—Dermatitis—Gemcitabine—lung cancer	0.000131	0.000264	CcSEcCtD
Pergolide—Headache—Gemcitabine—lung cancer	0.00013	0.000263	CcSEcCtD
Pergolide—Rhinitis—Doxorubicin—lung cancer	0.00013	0.000262	CcSEcCtD
Pergolide—Dyspepsia—Docetaxel—lung cancer	0.00013	0.000262	CcSEcCtD
Pergolide—Hepatitis—Doxorubicin—lung cancer	0.000129	0.000261	CcSEcCtD
Pergolide—Pharyngitis—Doxorubicin—lung cancer	0.000128	0.000259	CcSEcCtD
Pergolide—Decreased appetite—Docetaxel—lung cancer	0.000128	0.000259	CcSEcCtD
Pergolide—Oedema peripheral—Doxorubicin—lung cancer	0.000127	0.000257	CcSEcCtD
Pergolide—Dysgeusia—Methotrexate—lung cancer	0.000127	0.000257	CcSEcCtD
Pergolide—Asthenia—Etoposide—lung cancer	0.000127	0.000257	CcSEcCtD
Pergolide—Nausea—Irinotecan—lung cancer	0.000127	0.000256	CcSEcCtD
Pergolide—Pain—Docetaxel—lung cancer	0.000126	0.000254	CcSEcCtD
Pergolide—Constipation—Docetaxel—lung cancer	0.000126	0.000254	CcSEcCtD
Pergolide—Back pain—Methotrexate—lung cancer	0.000126	0.000254	CcSEcCtD
Pergolide—Pruritus—Etoposide—lung cancer	0.000125	0.000253	CcSEcCtD
Pergolide—Visual impairment—Doxorubicin—lung cancer	0.000125	0.000252	CcSEcCtD
Pergolide—Asthenia—Paclitaxel—lung cancer	0.000125	0.000252	CcSEcCtD
Pergolide—Nausea—Gemcitabine—lung cancer	0.000123	0.000249	CcSEcCtD
Pergolide—Vomiting—Cisplatin—lung cancer	0.000123	0.000248	CcSEcCtD
Pergolide—Pruritus—Paclitaxel—lung cancer	0.000123	0.000248	CcSEcCtD
Pergolide—Rash—Cisplatin—lung cancer	0.000122	0.000246	CcSEcCtD
Pergolide—Dermatitis—Cisplatin—lung cancer	0.000122	0.000246	CcSEcCtD
Pergolide—Feeling abnormal—Docetaxel—lung cancer	0.000121	0.000245	CcSEcCtD
Pergolide—Diarrhoea—Etoposide—lung cancer	0.000121	0.000245	CcSEcCtD
Pergolide—Eye disorder—Doxorubicin—lung cancer	0.000121	0.000244	CcSEcCtD
Pergolide—Ill-defined disorder—Methotrexate—lung cancer	0.000121	0.000244	CcSEcCtD
Pergolide—Tinnitus—Doxorubicin—lung cancer	0.000121	0.000244	CcSEcCtD
Pergolide—Gastrointestinal pain—Docetaxel—lung cancer	0.00012	0.000243	CcSEcCtD
Pergolide—Anaemia—Methotrexate—lung cancer	0.00012	0.000243	CcSEcCtD
Pergolide—Diarrhoea—Paclitaxel—lung cancer	0.000119	0.00024	CcSEcCtD
Pergolide—Malaise—Methotrexate—lung cancer	0.000117	0.000237	CcSEcCtD
Pergolide—Dizziness—Etoposide—lung cancer	0.000117	0.000237	CcSEcCtD
Pergolide—Vertigo—Methotrexate—lung cancer	0.000117	0.000236	CcSEcCtD
Pergolide—Body temperature increased—Docetaxel—lung cancer	0.000116	0.000235	CcSEcCtD
Pergolide—Abdominal pain—Docetaxel—lung cancer	0.000116	0.000235	CcSEcCtD
Pergolide—Leukopenia—Methotrexate—lung cancer	0.000116	0.000235	CcSEcCtD
Pergolide—Chills—Doxorubicin—lung cancer	0.000116	0.000235	CcSEcCtD
Pergolide—Arrhythmia—Doxorubicin—lung cancer	0.000116	0.000233	CcSEcCtD
Pergolide—Dizziness—Paclitaxel—lung cancer	0.000115	0.000232	CcSEcCtD
Pergolide—Nausea—Cisplatin—lung cancer	0.000115	0.000232	CcSEcCtD
Pergolide—Alopecia—Doxorubicin—lung cancer	0.000114	0.000231	CcSEcCtD
Pergolide—Cough—Methotrexate—lung cancer	0.000114	0.000229	CcSEcCtD
Pergolide—Convulsion—Methotrexate—lung cancer	0.000113	0.000228	CcSEcCtD
Pergolide—Vomiting—Etoposide—lung cancer	0.000113	0.000228	CcSEcCtD
Pergolide—Rash—Etoposide—lung cancer	0.000112	0.000226	CcSEcCtD
Pergolide—Dermatitis—Etoposide—lung cancer	0.000112	0.000226	CcSEcCtD
Pergolide—Headache—Etoposide—lung cancer	0.000111	0.000224	CcSEcCtD
Pergolide—Flatulence—Doxorubicin—lung cancer	0.000111	0.000224	CcSEcCtD
Pergolide—Arthralgia—Methotrexate—lung cancer	0.000111	0.000224	CcSEcCtD
Pergolide—Chest pain—Methotrexate—lung cancer	0.000111	0.000224	CcSEcCtD
Pergolide—Myalgia—Methotrexate—lung cancer	0.000111	0.000224	CcSEcCtD
Pergolide—Tension—Doxorubicin—lung cancer	0.000111	0.000223	CcSEcCtD
Pergolide—Vomiting—Paclitaxel—lung cancer	0.000111	0.000223	CcSEcCtD
Pergolide—Dysgeusia—Doxorubicin—lung cancer	0.00011	0.000223	CcSEcCtD
Pergolide—Rash—Paclitaxel—lung cancer	0.00011	0.000221	CcSEcCtD
Pergolide—Dermatitis—Paclitaxel—lung cancer	0.000109	0.000221	CcSEcCtD
Pergolide—Discomfort—Methotrexate—lung cancer	0.000109	0.000221	CcSEcCtD
Pergolide—Nervousness—Doxorubicin—lung cancer	0.000109	0.000221	CcSEcCtD
Pergolide—Back pain—Doxorubicin—lung cancer	0.000109	0.00022	CcSEcCtD
Pergolide—Headache—Paclitaxel—lung cancer	0.000109	0.00022	CcSEcCtD
Pergolide—Confusional state—Methotrexate—lung cancer	0.000107	0.000216	CcSEcCtD
Pergolide—Asthenia—Docetaxel—lung cancer	0.000106	0.000213	CcSEcCtD
Pergolide—Infection—Methotrexate—lung cancer	0.000105	0.000213	CcSEcCtD
Pergolide—Nausea—Etoposide—lung cancer	0.000105	0.000213	CcSEcCtD
Pergolide—Ill-defined disorder—Doxorubicin—lung cancer	0.000105	0.000211	CcSEcCtD
Pergolide—Pruritus—Docetaxel—lung cancer	0.000104	0.00021	CcSEcCtD
Pergolide—Anaemia—Doxorubicin—lung cancer	0.000104	0.00021	CcSEcCtD
Pergolide—Thrombocytopenia—Methotrexate—lung cancer	0.000104	0.00021	CcSEcCtD
Pergolide—Agitation—Doxorubicin—lung cancer	0.000104	0.000209	CcSEcCtD
Pergolide—Nausea—Paclitaxel—lung cancer	0.000103	0.000209	CcSEcCtD
Pergolide—Hyperhidrosis—Methotrexate—lung cancer	0.000103	0.000207	CcSEcCtD
Pergolide—Malaise—Doxorubicin—lung cancer	0.000102	0.000205	CcSEcCtD
Pergolide—Vertigo—Doxorubicin—lung cancer	0.000101	0.000204	CcSEcCtD
Pergolide—Anorexia—Methotrexate—lung cancer	0.000101	0.000204	CcSEcCtD
Pergolide—Syncope—Doxorubicin—lung cancer	0.000101	0.000204	CcSEcCtD
Pergolide—Leukopenia—Doxorubicin—lung cancer	0.000101	0.000204	CcSEcCtD
Pergolide—Diarrhoea—Docetaxel—lung cancer	0.000101	0.000204	CcSEcCtD
Pergolide—Palpitations—Doxorubicin—lung cancer	9.96e-05	0.000201	CcSEcCtD
Pergolide—Hypotension—Methotrexate—lung cancer	9.92e-05	0.0002	CcSEcCtD
Pergolide—Loss of consciousness—Doxorubicin—lung cancer	9.9e-05	0.0002	CcSEcCtD
Pergolide—Cough—Doxorubicin—lung cancer	9.83e-05	0.000199	CcSEcCtD
Pergolide—Convulsion—Doxorubicin—lung cancer	9.76e-05	0.000197	CcSEcCtD
Pergolide—Dizziness—Docetaxel—lung cancer	9.74e-05	0.000197	CcSEcCtD
Pergolide—Hypertension—Doxorubicin—lung cancer	9.73e-05	0.000196	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Methotrexate—lung cancer	9.67e-05	0.000195	CcSEcCtD
Pergolide—Insomnia—Methotrexate—lung cancer	9.6e-05	0.000194	CcSEcCtD
Pergolide—Arthralgia—Doxorubicin—lung cancer	9.59e-05	0.000194	CcSEcCtD
Pergolide—Myalgia—Doxorubicin—lung cancer	9.59e-05	0.000194	CcSEcCtD
Pergolide—Chest pain—Doxorubicin—lung cancer	9.59e-05	0.000194	CcSEcCtD
Pergolide—Anxiety—Doxorubicin—lung cancer	9.56e-05	0.000193	CcSEcCtD
Pergolide—Paraesthesia—Methotrexate—lung cancer	9.53e-05	0.000193	CcSEcCtD
Pergolide—Discomfort—Doxorubicin—lung cancer	9.48e-05	0.000191	CcSEcCtD
Pergolide—Dyspnoea—Methotrexate—lung cancer	9.47e-05	0.000191	CcSEcCtD
Pergolide—Somnolence—Methotrexate—lung cancer	9.44e-05	0.000191	CcSEcCtD
Pergolide—Dry mouth—Doxorubicin—lung cancer	9.38e-05	0.000189	CcSEcCtD
Pergolide—Vomiting—Docetaxel—lung cancer	9.37e-05	0.000189	CcSEcCtD
Pergolide—Dyspepsia—Methotrexate—lung cancer	9.35e-05	0.000189	CcSEcCtD
Pergolide—Rash—Docetaxel—lung cancer	9.29e-05	0.000188	CcSEcCtD
Pergolide—Dermatitis—Docetaxel—lung cancer	9.28e-05	0.000187	CcSEcCtD
Pergolide—Confusional state—Doxorubicin—lung cancer	9.27e-05	0.000187	CcSEcCtD
Pergolide—Decreased appetite—Methotrexate—lung cancer	9.23e-05	0.000186	CcSEcCtD
Pergolide—Headache—Docetaxel—lung cancer	9.23e-05	0.000186	CcSEcCtD
Pergolide—Oedema—Doxorubicin—lung cancer	9.19e-05	0.000186	CcSEcCtD
Pergolide—Infection—Doxorubicin—lung cancer	9.13e-05	0.000184	CcSEcCtD
Pergolide—Pain—Methotrexate—lung cancer	9.08e-05	0.000183	CcSEcCtD
Pergolide—Shock—Doxorubicin—lung cancer	9.05e-05	0.000183	CcSEcCtD
Pergolide—Thrombocytopenia—Doxorubicin—lung cancer	9e-05	0.000182	CcSEcCtD
Pergolide—Tachycardia—Doxorubicin—lung cancer	8.97e-05	0.000181	CcSEcCtD
Pergolide—Hyperhidrosis—Doxorubicin—lung cancer	8.89e-05	0.00018	CcSEcCtD
Pergolide—Anorexia—Doxorubicin—lung cancer	8.76e-05	0.000177	CcSEcCtD
Pergolide—Nausea—Docetaxel—lung cancer	8.75e-05	0.000177	CcSEcCtD
Pergolide—Feeling abnormal—Methotrexate—lung cancer	8.75e-05	0.000177	CcSEcCtD
Pergolide—Gastrointestinal pain—Methotrexate—lung cancer	8.68e-05	0.000175	CcSEcCtD
Pergolide—Hypotension—Doxorubicin—lung cancer	8.59e-05	0.000174	CcSEcCtD
Pergolide—Abdominal pain—Methotrexate—lung cancer	8.39e-05	0.00017	CcSEcCtD
Pergolide—Body temperature increased—Methotrexate—lung cancer	8.39e-05	0.00017	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Doxorubicin—lung cancer	8.38e-05	0.000169	CcSEcCtD
Pergolide—Insomnia—Doxorubicin—lung cancer	8.32e-05	0.000168	CcSEcCtD
Pergolide—Paraesthesia—Doxorubicin—lung cancer	8.26e-05	0.000167	CcSEcCtD
Pergolide—Dyspnoea—Doxorubicin—lung cancer	8.2e-05	0.000166	CcSEcCtD
Pergolide—Somnolence—Doxorubicin—lung cancer	8.17e-05	0.000165	CcSEcCtD
Pergolide—Dyspepsia—Doxorubicin—lung cancer	8.09e-05	0.000163	CcSEcCtD
Pergolide—Decreased appetite—Doxorubicin—lung cancer	7.99e-05	0.000161	CcSEcCtD
Pergolide—Pain—Doxorubicin—lung cancer	7.86e-05	0.000159	CcSEcCtD
Pergolide—Constipation—Doxorubicin—lung cancer	7.86e-05	0.000159	CcSEcCtD
Pergolide—Asthenia—Methotrexate—lung cancer	7.62e-05	0.000154	CcSEcCtD
Pergolide—Feeling abnormal—Doxorubicin—lung cancer	7.58e-05	0.000153	CcSEcCtD
Pergolide—Gastrointestinal pain—Doxorubicin—lung cancer	7.52e-05	0.000152	CcSEcCtD
Pergolide—Pruritus—Methotrexate—lung cancer	7.51e-05	0.000152	CcSEcCtD
Pergolide—Abdominal pain—Doxorubicin—lung cancer	7.27e-05	0.000147	CcSEcCtD
Pergolide—Body temperature increased—Doxorubicin—lung cancer	7.27e-05	0.000147	CcSEcCtD
Pergolide—Diarrhoea—Methotrexate—lung cancer	7.27e-05	0.000147	CcSEcCtD
Pergolide—Dizziness—Methotrexate—lung cancer	7.02e-05	0.000142	CcSEcCtD
Pergolide—Vomiting—Methotrexate—lung cancer	6.75e-05	0.000136	CcSEcCtD
Pergolide—Rash—Methotrexate—lung cancer	6.69e-05	0.000135	CcSEcCtD
Pergolide—Dermatitis—Methotrexate—lung cancer	6.69e-05	0.000135	CcSEcCtD
Pergolide—Headache—Methotrexate—lung cancer	6.65e-05	0.000134	CcSEcCtD
Pergolide—Asthenia—Doxorubicin—lung cancer	6.6e-05	0.000133	CcSEcCtD
Pergolide—Pruritus—Doxorubicin—lung cancer	6.5e-05	0.000131	CcSEcCtD
Pergolide—Nausea—Methotrexate—lung cancer	6.31e-05	0.000127	CcSEcCtD
Pergolide—Diarrhoea—Doxorubicin—lung cancer	6.29e-05	0.000127	CcSEcCtD
Pergolide—Dizziness—Doxorubicin—lung cancer	6.08e-05	0.000123	CcSEcCtD
Pergolide—Vomiting—Doxorubicin—lung cancer	5.85e-05	0.000118	CcSEcCtD
Pergolide—Rash—Doxorubicin—lung cancer	5.8e-05	0.000117	CcSEcCtD
Pergolide—Dermatitis—Doxorubicin—lung cancer	5.79e-05	0.000117	CcSEcCtD
Pergolide—Headache—Doxorubicin—lung cancer	5.76e-05	0.000116	CcSEcCtD
Pergolide—Nausea—Doxorubicin—lung cancer	5.46e-05	0.00011	CcSEcCtD
Pergolide—DRD1—Signaling Pathways—EGFR—lung cancer	7.26e-06	3.46e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—AKT1—lung cancer	7.25e-06	3.46e-05	CbGpPWpGaD
Pergolide—DRD2—GPCR downstream signaling—AKT1—lung cancer	7.25e-06	3.45e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CXCL8—lung cancer	7.23e-06	3.44e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTEN—lung cancer	7.22e-06	3.44e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—PIK3CA—lung cancer	7.21e-06	3.44e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—VEGFA—lung cancer	7.19e-06	3.43e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MDM2—lung cancer	7.18e-06	3.42e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—lung cancer	7.18e-06	3.42e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CASP3—lung cancer	7.18e-06	3.42e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL2—lung cancer	7.17e-06	3.42e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—EGFR—lung cancer	7.16e-06	3.41e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—EGFR—lung cancer	7.16e-06	3.41e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—RAF1—lung cancer	7.16e-06	3.41e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—AKT1—lung cancer	7.14e-06	3.4e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—lung cancer	7.13e-06	3.4e-05	CbGpPWpGaD
Pergolide—HTR2A—GPCR downstream signaling—AKT1—lung cancer	7.13e-06	3.4e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—SRC—lung cancer	7.12e-06	3.4e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—STAT3—lung cancer	7.12e-06	3.39e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—PIK3CA—lung cancer	7.11e-06	3.39e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CG—lung cancer	7.11e-06	3.39e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—lung cancer	7.1e-06	3.38e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EP300—lung cancer	7.09e-06	3.38e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—SRC—lung cancer	7.09e-06	3.38e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—ERBB2—lung cancer	7.08e-06	3.37e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CASP3—lung cancer	7.06e-06	3.37e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL2—lung cancer	7.05e-06	3.36e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—lung cancer	7.03e-06	3.35e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—lung cancer	7.02e-06	3.34e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—PIK3CA—lung cancer	7e-06	3.34e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CCND1—lung cancer	6.99e-06	3.33e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MTOR—lung cancer	6.99e-06	3.33e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CB—lung cancer	6.99e-06	3.33e-05	CbGpPWpGaD
Pergolide—ADRA1A—GPCR downstream signaling—AKT1—lung cancer	6.98e-06	3.33e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EP300—lung cancer	6.98e-06	3.33e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—JUN—lung cancer	6.97e-06	3.32e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—VEGFA—lung cancer	6.94e-06	3.31e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CASP3—lung cancer	6.92e-06	3.3e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL2—lung cancer	6.91e-06	3.29e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—VEGFA—lung cancer	6.9e-06	3.29e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—SRC—lung cancer	6.89e-06	3.29e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—EP300—lung cancer	6.89e-06	3.28e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—lung cancer	6.88e-06	3.28e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CCND1—lung cancer	6.87e-06	3.28e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—lung cancer	6.87e-06	3.28e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—STAT3—lung cancer	6.87e-06	3.27e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—JUN—lung cancer	6.86e-06	3.27e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—lung cancer	6.86e-06	3.27e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—lung cancer	6.85e-06	3.27e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—STAT3—lung cancer	6.83e-06	3.26e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—lung cancer	6.82e-06	3.25e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTP1—lung cancer	6.81e-06	3.25e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MAPK3—lung cancer	6.8e-06	3.24e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—SRC—lung cancer	6.78e-06	3.23e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MMP9—lung cancer	6.78e-06	3.23e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—lung cancer	6.77e-06	3.23e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—lung cancer	6.77e-06	3.23e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—lung cancer	6.77e-06	3.23e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—POMC—lung cancer	6.76e-06	3.22e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—CDKN1A—lung cancer	6.76e-06	3.22e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTEN—lung cancer	6.74e-06	3.21e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CCND1—lung cancer	6.73e-06	3.21e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—lung cancer	6.72e-06	3.2e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—JUN—lung cancer	6.72e-06	3.2e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CXCL8—lung cancer	6.71e-06	3.2e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—VEGFA—lung cancer	6.71e-06	3.2e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—PIK3CA—lung cancer	6.68e-06	3.18e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MMP9—lung cancer	6.67e-06	3.18e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—lung cancer	6.67e-06	3.18e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—CDKN1A—lung cancer	6.65e-06	3.17e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—STAT3—lung cancer	6.65e-06	3.17e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTEN—lung cancer	6.64e-06	3.16e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—lung cancer	6.63e-06	3.16e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CAT—lung cancer	6.62e-06	3.16e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—MYC—lung cancer	6.61e-06	3.15e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—VEGFA—lung cancer	6.61e-06	3.15e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CREBBP—lung cancer	6.59e-06	3.14e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—lung cancer	6.58e-06	3.14e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—AKT1—lung cancer	6.58e-06	3.14e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MAPK3—lung cancer	6.56e-06	3.13e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—STAT3—lung cancer	6.54e-06	3.12e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MMP9—lung cancer	6.54e-06	3.12e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MAPK3—lung cancer	6.53e-06	3.11e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—lung cancer	6.53e-06	3.11e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—CDKN1A—lung cancer	6.51e-06	3.1e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTEN—lung cancer	6.5e-06	3.1e-05	CbGpPWpGaD
Pergolide—ADRA2A—GPCR downstream signaling—AKT1—lung cancer	6.49e-06	3.09e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—lung cancer	6.48e-06	3.09e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—AKT1—lung cancer	6.47e-06	3.09e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—EGFR—lung cancer	6.47e-06	3.08e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—lung cancer	6.46e-06	3.08e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ABCB1—lung cancer	6.44e-06	3.07e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—lung cancer	6.43e-06	3.07e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EP300—lung cancer	6.43e-06	3.07e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CASP3—lung cancer	6.43e-06	3.06e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL2—lung cancer	6.42e-06	3.06e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—lung cancer	6.38e-06	3.04e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—MYC—lung cancer	6.38e-06	3.04e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MAPK3—lung cancer	6.35e-06	3.03e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—MYC—lung cancer	6.35e-06	3.03e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—AKT1—lung cancer	6.34e-06	3.02e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—TYMS—lung cancer	6.33e-06	3.02e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EP300—lung cancer	6.33e-06	3.02e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—PIK3CA—lung cancer	6.3e-06	3e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—lung cancer	6.3e-06	3e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PIK3CA—lung cancer	6.27e-06	2.99e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—GSTM1—lung cancer	6.26e-06	2.98e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CCND1—lung cancer	6.25e-06	2.98e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SRC—lung cancer	6.25e-06	2.98e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MAPK3—lung cancer	6.25e-06	2.98e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CD—lung cancer	6.25e-06	2.98e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—EGFR—lung cancer	6.24e-06	2.98e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—JUN—lung cancer	6.24e-06	2.97e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—PIK3CA—lung cancer	6.22e-06	2.96e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—PIK3CA—lung cancer	6.22e-06	2.96e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—EGFR—lung cancer	6.21e-06	2.96e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—lung cancer	6.2e-06	2.95e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EP300—lung cancer	6.2e-06	2.95e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—lung cancer	6.18e-06	2.95e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—MYC—lung cancer	6.18e-06	2.94e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ALB—lung cancer	6.17e-06	2.94e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SRC—lung cancer	6.15e-06	2.93e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—lung cancer	6.11e-06	2.91e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—lung cancer	6.1e-06	2.91e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—VEGFA—lung cancer	6.09e-06	2.9e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—MYC—lung cancer	6.08e-06	2.9e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MMP9—lung cancer	6.07e-06	2.89e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—CDKN1A—lung cancer	6.05e-06	2.88e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—EGFR—lung cancer	6.04e-06	2.88e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTEN—lung cancer	6.04e-06	2.88e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—STAT3—lung cancer	6.03e-06	2.87e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SRC—lung cancer	6.03e-06	2.87e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—lung cancer	6.02e-06	2.87e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—lung cancer	6.01e-06	2.87e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—lung cancer	6.01e-06	2.87e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—VEGFA—lung cancer	5.99e-06	2.86e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—EGFR—lung cancer	5.95e-06	2.83e-05	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—AKT1—lung cancer	5.93e-06	2.83e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—STAT3—lung cancer	5.93e-06	2.83e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CYP1A1—lung cancer	5.93e-06	2.83e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—lung cancer	5.92e-06	2.82e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—lung cancer	5.92e-06	2.82e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—lung cancer	5.9e-06	2.81e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—AKT1—lung cancer	5.89e-06	2.81e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ERCC2—lung cancer	5.88e-06	2.8e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—VEGFA—lung cancer	5.87e-06	2.8e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—lung cancer	5.87e-06	2.8e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—lung cancer	5.83e-06	2.78e-05	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—AKT1—lung cancer	5.81e-06	2.77e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—STAT3—lung cancer	5.81e-06	2.77e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—lung cancer	5.8e-06	2.76e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MAPK3—lung cancer	5.76e-06	2.75e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EP300—lung cancer	5.76e-06	2.74e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—lung cancer	5.75e-06	2.74e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—lung cancer	5.75e-06	2.74e-05	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—AKT1—lung cancer	5.72e-06	2.73e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—lung cancer	5.71e-06	2.72e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MAPK3—lung cancer	5.67e-06	2.7e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—lung cancer	5.62e-06	2.68e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—PIK3CA—lung cancer	5.61e-06	2.68e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—MYC—lung cancer	5.6e-06	2.67e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SRC—lung cancer	5.6e-06	2.67e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—lung cancer	5.58e-06	2.66e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MAPK3—lung cancer	5.55e-06	2.65e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—MYC—lung cancer	5.51e-06	2.63e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—lung cancer	5.51e-06	2.62e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—lung cancer	5.51e-06	2.62e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—EGFR—lung cancer	5.48e-06	2.61e-05	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—AKT1—lung cancer	5.46e-06	2.6e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—VEGFA—lung cancer	5.45e-06	2.6e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CB—lung cancer	5.44e-06	2.6e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—lung cancer	5.43e-06	2.59e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PIK3CA—lung cancer	5.42e-06	2.58e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—MYC—lung cancer	5.4e-06	2.57e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—STAT3—lung cancer	5.4e-06	2.57e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—lung cancer	5.39e-06	2.57e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—EGFR—lung cancer	5.39e-06	2.57e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PIK3CA—lung cancer	5.39e-06	2.57e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—lung cancer	5.39e-06	2.57e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—EGFR—lung cancer	5.28e-06	2.52e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PIK3CA—lung cancer	5.24e-06	2.5e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—lung cancer	5.24e-06	2.5e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—lung cancer	5.22e-06	2.49e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—lung cancer	5.19e-06	2.48e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—lung cancer	5.18e-06	2.47e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PIK3CA—lung cancer	5.16e-06	2.46e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MAPK3—lung cancer	5.16e-06	2.46e-05	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—AKT1—lung cancer	5.15e-06	2.45e-05	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—AKT1—lung cancer	5.12e-06	2.44e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—lung cancer	5.1e-06	2.43e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PIK3CA—lung cancer	5.09e-06	2.43e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—APOA1—lung cancer	5.09e-06	2.43e-05	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—AKT1—lung cancer	5.08e-06	2.42e-05	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—AKT1—lung cancer	5.08e-06	2.42e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—lung cancer	5.07e-06	2.42e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—MYC—lung cancer	5.02e-06	2.39e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—lung cancer	5.01e-06	2.39e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—lung cancer	4.99e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—lung cancer	4.99e-06	2.38e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—lung cancer	4.99e-06	2.38e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—lung cancer	4.97e-06	2.37e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—EGFR—lung cancer	4.91e-06	2.34e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—lung cancer	4.85e-06	2.31e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—lung cancer	4.8e-06	2.29e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—lung cancer	4.77e-06	2.28e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—lung cancer	4.77e-06	2.28e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PIK3CA—lung cancer	4.76e-06	2.27e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTEN—lung cancer	4.7e-06	2.24e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PIK3CA—lung cancer	4.68e-06	2.23e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CG—lung cancer	4.65e-06	2.21e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—lung cancer	4.64e-06	2.21e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—lung cancer	4.64e-06	2.21e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—lung cancer	4.6e-06	2.19e-05	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—AKT1—lung cancer	4.59e-06	2.19e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PIK3CA—lung cancer	4.58e-06	2.18e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—lung cancer	4.57e-06	2.18e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—lung cancer	4.53e-06	2.16e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—EP300—lung cancer	4.49e-06	2.14e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—lung cancer	4.43e-06	2.11e-05	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—AKT1—lung cancer	4.43e-06	2.11e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—POMC—lung cancer	4.42e-06	2.11e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—AKT1—lung cancer	4.4e-06	2.1e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—lung cancer	4.4e-06	2.1e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—lung cancer	4.33e-06	2.06e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CREBBP—lung cancer	4.31e-06	2.05e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—AKT1—lung cancer	4.28e-06	2.04e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PIK3CA—lung cancer	4.26e-06	2.03e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—lung cancer	4.24e-06	2.02e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—AKT1—lung cancer	4.22e-06	2.01e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—lung cancer	4.21e-06	2.01e-05	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—AKT1—lung cancer	4.16e-06	1.98e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—lung cancer	4.15e-06	1.98e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—lung cancer	4.12e-06	1.96e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CD—lung cancer	4.08e-06	1.95e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—lung cancer	4.06e-06	1.93e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ALB—lung cancer	4.03e-06	1.92e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—lung cancer	3.94e-06	1.88e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—AKT1—lung cancer	3.89e-06	1.85e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—AKT1—lung cancer	3.82e-06	1.82e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—lung cancer	3.77e-06	1.8e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—AKT1—lung cancer	3.74e-06	1.78e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CB—lung cancer	3.56e-06	1.7e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—lung cancer	3.53e-06	1.68e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—AKT1—lung cancer	3.48e-06	1.66e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PIK3CA—lung cancer	3.32e-06	1.58e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTEN—lung cancer	3.08e-06	1.47e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—EP300—lung cancer	2.93e-06	1.4e-05	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—AKT1—lung cancer	2.71e-06	1.29e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PIK3CA—lung cancer	2.17e-06	1.03e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—AKT1—lung cancer	1.77e-06	8.45e-06	CbGpPWpGaD
